Skip to main content

Table 4 Univariate analyses of risk factors for OS and PFS

From: Role of the initial degree of anaemia and treatment model in the prognosis of gastric cancer patients treated by chemotherapy: a retrospective analysis

 

N = 598

OS

PFS

p value

HR

95%CI

 

p value

HR

95%CI

HBini

 

0.010

0.995

0.991–0.999

0.013

0.995

0.992–0.999

HBlowest

 

0.575

0.999

0.995–1.003

0.010

0.995

0.992–0.999

HBini ≤ 80 g/L

40(6.7)

0.012

1.608

1.109–2.332

0.065

1.371

0.981–1.916

HBini > 80 g/L

558(93.3)

      

Metastases

 Metastatic sites ≥3

127(21.2)

0.033

1.268

1.020–1.577

0.015

1.289

1.050–1.583

 Metastatic sites < 3

471(78.8)

      

  Lymph node

457(76.4)

0.849

0.980

0.794–1.209

0.276

0.896

0.734–1.092

  Liver

246(41.1)

0.010

1.271

1.059–1.525

0.001

1.354

1.141–1.607

  Lung

99(16.6)

0.399

0.899

0.703–1.151

0.221

1.150

0.920–1.438

  Bone

25(4.2)

0.072

1.495

0.964–2.318

0.017

1.651

1.093–2.493

  Peritoneum

67(11.20)

0.181

0.821

0.651–1.096

0.771

0.960

0.729–1.264

Chemotherapy regimen

 Included paclitaxel

239(40.0)

0.116

1.160

0.964–1.397

0.018

1.232

1.037–1.463

 Included platinum

61(10.2)

0.290

0.849

0.626–1.150

0.734

0.985

0.748–1.296

Number of cycles

 

< 0.001

0.916

0.894–0.940

0.006

0.97

0.948–0.991

Number of PTX3*

 

0.023

0.937

0.885–0.991

0.940

1.002

0.955–1.051

Treatment response

 Progressive disease

188(31.4)

0.041

1.223

1.008–1.484

< 0.001

1.959

1.634–2.350

 Non-progressive disease

410(68.6)

      

HBdec

  ≥ 30

131(21.9)

0.048

1.244

1.002–1.546

< 0.001

1.594

1.302–1.951

  < 30

467(78.1)

      

Transfusion

87(14.5)

0.778

1.038

0.802–1.342

0.492

1.085

0.860–1.367

No transfusion

511(85.5)

      

Adjuvant chemotherapy

170

0.735

1.010

0.954–1.070

0.470

0.981

0.931–1.034

  1. *PTX3 paclitaxel-based combination of three regimens